ReviewCancer drug resistance (Alhambra, Calif.)2019

Targeting MYCN and ALK in resistant and relapsing neuroblastoma.

Elizabeth R Tucker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.